DIHUA YU to Immunotherapy
This is a "connection" page, showing publications DIHUA YU has written about Immunotherapy.
Connection Strength
0.758
-
The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell. 2022 01 10; 40(1):36-52.e9.
Score: 0.302
-
Brain Metastasis Organotropism. Cold Spring Harb Perspect Med. 2020 05 01; 10(5).
Score: 0.271
-
Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1. Cancer Discov. 2022 07 06; 12(7):1742-1759.
Score: 0.079
-
The impact of PD-L1?N-linked glycosylation on cancer therapy and clinical diagnosis. J Biomed Sci. 2020 Jul 03; 27(1):77.
Score: 0.069
-
An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response. STAR Protoc. 2022 03 18; 3(1):101198.
Score: 0.019
-
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021 02 05; 12(1):832.
Score: 0.018